You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明康德(603259.SH):擬1000萬歐元認購私募基金份額
格隆匯 11-15 17:05

格隆匯11月15日丨藥明康德(603259.SH)公佈,全資子企業WuXiPharmaTechHealthcareFundIL.P.(簡稱“WuXiFundI”)與SofinnovaCapitalXIGPS.àr.l.(簡稱“普通合夥人”)簽署SubscriptionAgreement(簡稱“認購協議”),約定由WuXiFundI認繳SofinnovaCapitalXISCSpSICAV-RAIF(簡稱“投資基金”)1,000萬歐元的投資基金份額,約佔已募集投資基金份額的4.40%(WuXiFundI所持投資基金份額比例將隨投資基金後續募集金額增加而進一步稀釋)。截至本公吿日,WuXiFundI尚未支付投資款,後續WuXiFundI將以自有資金根據認購協議的要求履行投資款的支付義務。投資基金主要專注於在世界範圍內投資生命科學領域(特別是生物醫藥及醫療器械行業)的初創企業。投資基金約70%的資金投資於歐洲區域內的初創企業,約30%的資金用於歐洲以外區域的投資。

SofinnovaPartners是歐洲知名的生物科技投資機構,在歐洲生命科學領域擁有超過50年的行業經驗及卓越的投資記錄。投資基金聚焦於對歐洲早期階段的生物醫藥公司進行有影響力的投資,通過挖掘轉化高質量的科研成果,培育早期生物科技企業成為具備全球競爭力的生物科技公司。基金管理人已經建立了一個廣泛且值得信賴的企業家與科學家網絡,高度契合本公司賦能全球生物醫藥科學發展及促進科學轉化的戰略宗旨。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account